DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

Kashiv Biosciences, LLC

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

17 Comunicados de prensa

Ver todos los comunicados de prensa
22/04/2026
Multimedia
Mercado de valores
Salud
Ciencia
Sanidad
Farmacéutica
Biotecnología
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
14/04/2026
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
09/02/2026
Mercado laboral
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
06/01/2026
Biotecnología
Farmacéutica
Salud
Eventos
Ferias y Congresos
Kashiv BioSciences sarà presente alla 44ª conferenza annuale sulla sanità di J.P. Morgan
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
06/01/2026
Biotecnología
Farmacéutica
Salud
Eventos
Ferias y Congresos
Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
24/09/2025
Mercado laboral
Industria
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
11/09/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Mercado laboral
Industria
Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
05/08/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab)
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
25/06/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Industria
Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab)
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0
07/04/2025
Mercado laboral
Salud
Ciencia
Farmacéutica
Biotecnología
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
Fuente
Kashiv Biosciences, LLC
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0